Korean J Ophthalmol.  2005 Dec;19(4):297-301. 10.3341/kjo.2005.19.4.297.

The Effect of Latanoprost on Intraocular Pressure during 12 Months of Treatment for Normal-tension Glaucoma

• Oh JY
• Park KH

• KMID: 754443
• DOI: http://doi.org/10.3341/kjo.2005.19.4.297

Abstract

PURPOSE
To evaluate the intraocular pressure (IOP) -lowering efficacy of latanoprost in normal-tension glaucoma (NTG). METHODS: One-hundred and seventeen eyes of 63 NTG patients treated with 0.005% latanoprost once a day were enrolled in this study. Of these, 85 eyes of 47 patients were treated for 12 months. Mean IOPs were analyzed, and the mean IOP reductions from the untreated baseline were assessed after two weeks and after 1, 3, 6, 9, and 12 months of treatment. RESULTS: The mean untreated baseline IOP was 15.0+/-2.7 mmHg. After two weeks of latanoprost treatment, the mean IOP reduction from the baseline value was 2.6+/-0.2 mmHg (17.3%, p< 0.05), and after 6 and 12 months, the reduction was 2.4+/-0.2 mmHg (16.0%, p< 0.05) and 2.4+/-0.2 mmHg (16.0%, p< 0.05), respectively. Patients with a baseline IOP of > or=15 mmHg achieved significantly higher IOP reductions than those with a baseline IOP of < 15 mmHg at all follow-ups (p< 0.05). CONCLUSIONS: Latanoprost was found to be well tolerated and to significantly reduce IOP in NTG patients.

Keyword

Intraocular pressure; Intraocular pressure-lowering efficacy; Latanoprost; Normal-tension glaucoma

MeSH Terms

Treatment Outcome
Time Factors
Retrospective Studies
Prostaglandins F, Synthetic/administration & dosage/*therapeutic use
Middle Aged
Male
Intraocular Pressure/*drug effects/physiology
Humans
Glaucoma, Open-Angle/*drug therapy/physiopathology
Follow-Up Studies
Female
Dose-Response Relationship, Drug
Antihypertensive Agents/administration & dosage/*therapeutic use
Aged, 80 and over
Aged
Adult

Figure

• 

  Fig. 1 Mean intraocular pressure (IOP) at the untreated baseline and after two weeks to 12 months of latanoprost treatment (mean±95% confidence interval)

Reference

1. Levene RZ. Low tension glaucoma: a critical review and new material. Surv Ophthalmol. 1980. 24:621–624.

2. Hoyng PF, Kitazawa Y. Medical treatment of normal tension glaucoma. Surv Ophthalmol. 2002. 47:S116–S124.

3. Abedin S, Simmons RJ, Grant WM. Progressive low-tension glaucoma: treatment to stop glaucomatous cupping and field loss when these progress despite normal intraocular pressure. Ophthalmology. 1982. 89:1–6.

4. Bhandari A, Crabb DP, Poinoosawmy D, et al. Effect of surgery on visual field progression in normal-tension glaucoma. Ophthalmology. 1997. 104:1131–1137.

5. Daugeliene L, Yamamoto T, Kitazawa Y. Effect of trabeculectomy on visual field in progressive normal-tension glaucoma. Jpn J Ophthalmol. 1998. 42:286–292.

6. de Jong N, Greve EL, Hoyng PF, Geijssen HC. Results of a filtering procedure in low tension glaucoma. Int Ophthalmol. 1989. 13:131–138.

7. The Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998. 126:487–497.

8. The Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998. 126:498–505.

9. Drance SM, Crichton A, Mills RP. comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. Am J Ophthalmol. 1998. 125:585–592.

10. McKibbin M, Menage MJ. The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma. Eye. 1999. 13:31–34.

11. Georgopoulos GT, Diestelhorst M, Fisher R, et al. The short-term effect of latanoprost on intraocular pressure and pulsatile ocular blood flow. Acta Ophthalmol Scand. 2002. 80:54–58.

12. European Glaucoma Society. Traverso CE, editor. Antiglaucoma drugs. Terminology and Guidelines for Glaucoma. 2003. 2nd ed. European Glaucoma Society;Ch3-10-17.

13. Wolfinger RD. Covariance structure selection in general mixed models. Commun Stat Simul C. 1993. 22:1079–1106.

14. Rubin DB. Multiple Imputation for Nonresponse in Surveys. 1987. 1st ed. New York: John Wiley & Sons;202–215.

15. Schafer JL. Analysis of Incomplete Multivariate Data. 1997. 1st ed. New York: Chapman & Hall;333–372.

16. Cartwright MJ, Anderson DR. Correlation of asymmetric damage with asymmetric intraocular pressure in normal-tension glaucoma (low-tension glaucoma). Arch Ophthalmol. 1988. 106:888–890.

17. Crichton A, Drance SM, Douglas GR, Schulzer M. Unequal intraocular pressure and its relation to asymmetric visual field defects in low-tension glaucoma. Ophthalmology. 1989. 96:1312–1314.

18. Haefliger IO, Hitchings RA. Relation between asymmetry in visual field defects and intraocular pressure difference in an untreated normal (low) tension glaucoma population. Acta Ophthalmol. 1990. 68:564–567.

19. Jonas JB, Grundler AE, Gonzales-cortes J. Pressure-dependent neuroretinal rim loss in normal-tension glaucoma. Am J Ophthalmol. 1998. 125:137–144.

20. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41,a new prostaglandin F_2α analog, on aqueous humor dynamics in human eyes. Opthalmology. 1993. 100:1297–1304.

21. Alm A, Stjernschantz J. the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. Ophthalmology. 1995. 102:1743–1752.

22. Alm A, Widengard I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Opthalmol Scand. 2000. 78:71–76.

23. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. Ophthalmology. 1996. 103:138–147.

24. Watson PG. Latanoprost: Two years experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998. 105:82–87.

25. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Latanoprost Study Group. Ophthalmology. 1996. 103:126–137.

26. Mishima HK, Kiuchi Y, Takamatsu M. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol. 1997. 41:S139–S144.

27. Orzalesi N, Rossetti L, Invernizzi T, et al. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000. 41:2566–2573.

28. Tamada Y, Taniguchi T, Murase H, et al. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. J Ocul Pharmacol Ther. 2001. 17:19–25.

29. Rulo AH, Greve EL, Geijssen HC, Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal pressure glaucoma. Ophthalmology. 1996. 103:1276–1282.